Rankings
▼
Calendar
CTMX Q1 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$822M
Q1 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$12M
+424.2% YoY
Gross Profit
$12M
100.0% margin
Operating Income
-$9M
-73.9% margin
Net Income
-$8M
-70.9% margin
EPS (Diluted)
$-0.23
QoQ Revenue Growth
+85.8%
Cash Flow
Operating Cash Flow
-$19M
Free Cash Flow
-$20M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$178M
Total Liabilities
$104M
Stockholders' Equity
$74M
Cash & Equivalents
$86M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$12M
$2M
+424.2%
Gross Profit
$12M
$2M
+424.2%
Operating Income
-$9M
-$16M
+46.8%
Net Income
-$8M
-$16M
+48.5%
← FY 2017
All Quarters
Q2 2017 →